Fred Alger Management’s Heron Therapeutics HRTX Stock Holding History

Fred Alger Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-51,670	Closed	-$961K	–	512
2019 Q2	$961K	Buy	+51,670	New	+$1.03M	﹤0.01%	343
2018 Q4	–	Sell	-13,000	Closed	-$411K	–	538
2018 Q3	$411K	Buy	+13,000	New	+$484K	﹤0.01%	364
2016 Q4	–	Sell	-81,903	Closed	-$1.41M	–	501
2016 Q3	$1.41M	Sell	81,903 -18,232	-18%	-$338K	0.01%	281
2016 Q2	$1.81M	Sell	100,135 -71,098	-42%	-$1.39M	0.01%	281
2016 Q1	$3.25M	Sell	171,233 -73,407	-30%	-$1.45M	0.02%	294
2015 Q4	$6.53M	Sell	244,640 -9,057	-4%	-$242K	0.03%	224
2015 Q3	$6.19M	Buy	253,697 +62,547	+33%	+$2.08M	0.03%	250
2015 Q2	$5.96M	Buy	+191,150	New	+$3.6M	0.03%	283

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fred Alger Management's HRTX Position: Q3 2019 in Review

Fred Alger Management sold out of Heron Therapeutics (HRTX) in Q3 2019, closing a stake of 51,670 shares — an estimated $961K sold.

Fred Alger Management first reported a position in HRTX in Q2 2015 and held it in 8 quarters. The position peaked at $6.53M in Q4 2015. 180 funds tracked by Wall St. Rank hold HRTX as of Q3 2019.

Fred Alger Management reported no remaining Heron Therapeutics position as of Q3 2019 after selling out during the quarter.
Fred Alger Management sold 51,670 Heron Therapeutics shares in Q3 2019, an estimated $961K.
Fred Alger Management first reported a position in Heron Therapeutics in Q2 2015 and held it in 8 quarters.
Fred Alger Management's Heron Therapeutics position peaked at $6.53M in Q4 2015.
180 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2019.

Based on Fred Alger Management's 13F filing for Q3 2019, filed 14 Nov 2019.